<DOC>
	<DOCNO>NCT01266499</DOCNO>
	<brief_summary>Klebsiella pneumonia , inhabitant digestive tract , frequent nosocomial pathogen . It currently fourth common cause pneumonia fifth common cause bacteremia intensive care patient ( 1-3 ) . The aim present randomize control trial ass efficacy non-absorbable oral antibiotic eradication KPC carrier state .</brief_summary>
	<brief_title>A Study Evaluating Role Oral Antibiotics Aim Eradicate Carrier State Carbapenem- Resistant Klebsiella Pneumonia ( KPC ) .</brief_title>
	<detailed_description />
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Bacteremia</mesh_term>
	<mesh_term>Klebsiella Infections</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Colistin</mesh_term>
	<mesh_term>Polymyxins</mesh_term>
	<mesh_term>Gentamicins</mesh_term>
	<criteria>Inclusion Criteria 1 . Patient identify KPC carrier . 2 . Patient capable understand sign inform consent 3 . Age &gt; 18 4 . Patient capable receive oral medication 1 . Patient unable sign inform consent 2 . Age â‰¤ 18 3 . Pregnant/lactating female 4 . Patient expect survive &gt; 2 week . 5 . Patient unable allow receive oral medication 6 . A know allergy study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>Klebsiella , pneumonia , carbapenem-hydrolyzing lactamase , carbapenem-resistant Klebsiella ( KPC ) , eradication ,</keyword>
</DOC>